{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:13:38Z","timestamp":1788408818332,"version":"build-2803163510"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00473-5","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T02:46:28Z","timestamp":1787366788000},"page":"481-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5663-9781","authenticated-orcid":false,"given":"Andrew","family":"Carlson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid A.","family":"Zayyad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Driesenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Boxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atreya","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Uraizee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rediat","family":"Ephrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Natsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhir R.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"6","key":"473_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jacc.2022.05.033","volume":"80","author":"R Mohebi","year":"2020","unstructured":"Mohebi R, Chen C, Ibrahim NE, McCarthy CP, Gaggin HK, Singer DE, et al. Cardiovascular disease projections in the United States based on the 2020 census estimates. J Am Coll Cardiol. 2020;80(6):565\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2022.05.033.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"473_CR2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/clinchem\/hvad012","volume":"69","author":"NMA White-Al Habeeb","year":"2023","unstructured":"White-Al Habeeb NMA, Higgins V, Wolska A, Delaney SR, Remaley AT, Beriault DR. The present and future of lipid testing in cardiovascular risk assessment. Clin Chem. 2023;69(5):456\u201369. https:\/\/doi.org\/10.1093\/clinchem\/hvad012.","journal-title":"Clin Chem"},{"issue":"44","key":"473_CR3","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1093\/eurheartj\/ehaf606","volume":"46","author":"CM Ballantyne","year":"2025","unstructured":"Ballantyne CM, Norata GD. The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur Heart J. 2025;46(44):4737\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf606.","journal-title":"Eur Heart J"},{"issue":"11","key":"473_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028892","volume":"12","author":"MJ Wilkinson","year":"2023","unstructured":"Wilkinson MJ, Lepor NE, Michos ED. Evolving management of low\u2010density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum. J Am Heart Assoc. 2023;12(11):e028892. https:\/\/doi.org\/10.1161\/JAHA.122.028892.","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"473_CR5","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1016\/j.jacc.2021.04.052","volume":"77","author":"IM Graham","year":"2021","unstructured":"Graham IM, Di Angelantonio E, Visseren F, De Bacquer D, Ference BA, Timmis A, et al. Systematic coronary risk evaluation (SCORE). J Am Coll Cardiol. 2021;77(24):3046\u201357. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.052.","journal-title":"J Am Coll Cardiol"},{"key":"473_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.11.016","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, et al. ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia. JACC. 2026. https:\/\/doi.org\/10.1016\/j.jacc.2025.11.016.","journal-title":"JACC"},{"issue":"25","key":"473_CR7","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease. J Am Coll Cardiol. 2012;60(25):2631\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.09.017.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"473_CR8","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","volume":"6","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Pletcher MJ, Vittinghoff E, Clemons AM, Jacobs DR, Allen NB, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol. 2021;6(12):1406. https:\/\/doi.org\/10.1001\/jamacardio.2021.3508.","journal-title":"JAMA Cardiol"},{"issue":"9753","key":"473_CR9","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (Ctt) Collaboration","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (Ctt) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet. 2010;376(9753):1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","journal-title":"The Lancet"},{"issue":"32","key":"473_CR10","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"18","key":"473_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"25","key":"473_CR12","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"issue":"10","key":"473_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11100690","volume":"11","author":"J Behbodikhah","year":"2021","unstructured":"Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, De Leon J, Glass AD, et al. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites. 2021;11(10):690. https:\/\/doi.org\/10.3390\/metabo11100690.","journal-title":"Metabolites"},{"key":"473_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100649","volume":"18","author":"O Mhaimeed","year":"2024","unstructured":"Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better. Am J Prev Cardiol. 2024;18:100649. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100649.","journal-title":"Am J Prev Cardiol"},{"issue":"12","key":"473_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289. https:\/\/doi.org\/10.1001\/jama.2016.13985.","journal-title":"JAMA"},{"issue":"14","key":"473_CR16","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2023.07.027","volume":"82","author":"NW Andersson","year":"2023","unstructured":"Andersson NW, Corn G, Dohlmann TL, Melbye M, Wohlfahrt J, Lund M. LDL-C reduction with lipid-lowering therapy for primary prevention of major vascular events among older individuals. J Am Coll Cardiol. 2023;82(14):1381\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2023.07.027.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"473_CR17","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2210645.","journal-title":"N Engl J Med"},{"issue":"1","key":"473_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"issue":"22","key":"473_CR19","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"issue":"24","key":"473_CR20","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","unstructured":"The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1107579.","journal-title":"N Engl J Med"},{"issue":"15","key":"473_CR21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"N Engl J Med"},{"issue":"22","key":"473_CR22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"473_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.126.080616","author":"BA Bergmark","year":"2026","unstructured":"Bergmark BA, Bohula EA, Marston NA, Park JG, Kuder JF, Murphy SA, et al. Evolocumab in patients with prior percutaneous coronary intervention and no prior MI: results from the VESALIUS-CV trial. Circulation. 2026. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.126.080616.","journal-title":"Circulation"},{"issue":"2","key":"473_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2514428","volume":"394","author":"EA Bohula","year":"2026","unstructured":"Bohula EA, Marston NA, Bhatia AK, Ferrari GMD, Leiter LA, Nicolau JC, et al. Evolocumab in patients without a previous myocardial infarction or stroke. N Engl J Med. 2026;394(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2514428.","journal-title":"N Engl J Med"},{"key":"473_CR25","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-0847","author":"LA Leiter","year":"2026","unstructured":"Leiter LA, Giugliano RP, Marston NA, De Ferrari G, Nicolau JC, Bhatia AK, et al. Evolocumab in patients with high-risk diabetes: results from the VESALIUS-CV trial. Diabetes Care. 2026. https:\/\/doi.org\/10.2337\/dc26-0847.","journal-title":"Diabetes Care"},{"issue":"16","key":"473_CR26","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jama.2026.3277","volume":"335","author":"NA Marston","year":"2026","unstructured":"Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al. Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial. JAMA. 2026;335(16):1400\u20137. https:\/\/doi.org\/10.1001\/jama.2026.3277.","journal-title":"JAMA"},{"key":"473_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.126.080999","author":"V Monguillon","year":"2026","unstructured":"Monguillon V, Marston NA, Bohula EA, Park JG, Kuder JF, Murphy SA, et al. Lipoprotein(a) levels, risk of cardiovascular events and benefit of evolocumab: findings from the VESALIUS-CV trial. Circulation. 2026. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.126.080999.","journal-title":"Circulation"},{"issue":"1","key":"473_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56790-1","volume":"16","author":"QW Ren","year":"2025","unstructured":"Ren QW, Teng THK, Ouwerkerk W, Tse YK, Tsang CTW, Wu MZ, et al. Triglyceride levels and its association with all-cause mortality and cardiovascular outcomes among patients with heart failure. Nat Commun. 2025;16(1):1408. https:\/\/doi.org\/10.1038\/s41467-025-56790-1.","journal-title":"Nat Commun"},{"issue":"7","key":"473_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"473_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa2512761","volume":"394","author":"NA Marston","year":"2026","unstructured":"Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. N Engl J Med. 2026;394(5):429\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2512761.","journal-title":"N Engl J Med"},{"key":"473_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"issue":"14","key":"473_CR32","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2022;80(14):1366\u2013418. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.006.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"473_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"42","key":"473_CR34","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters Van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, et al. Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J"},{"issue":"2","key":"473_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","volume":"31","author":"SB Patel","year":"2025","unstructured":"Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S, et al. American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025;31(2):236\u201362. https:\/\/doi.org\/10.1016\/j.eprac.2024.09.016.","journal-title":"Endocr Pract"},{"issue":"25 Pt B","key":"473_CR36","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff","year":"2013","unstructured":"Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, et al. ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;63(25 Pt B):2935\u201359. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.005.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"473_CR37","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and validation of the American Heart Association\u2019s PREVENT equations. Circulation. 2024;149(6):430\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067626.","journal-title":"Circulation"},{"issue":"8","key":"473_CR38","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamainternmed.2024.1302","volume":"184","author":"TS Anderson","year":"2024","unstructured":"Anderson TS, Wilson LM, Sussman JB. Atherosclerotic cardiovascular disease risk estimates using the predicting risk of cardiovascular disease events equations. JAMA Intern Med. 2024;184(8):963\u201370. https:\/\/doi.org\/10.1001\/jamainternmed.2024.1302.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"473_CR39","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jacc.2014.06.1186","volume":"64","author":"KN Karmali","year":"2014","unstructured":"Karmali KN, Goff DC, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC\/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64(10):959\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1186.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"473_CR40","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1038\/s41591-025-03789-2","volume":"31","author":"RO Mathew","year":"2025","unstructured":"Mathew RO, Khan SS, Tuttle KR, Ho JE, Abramov D, Bangalore S, et al. Performance of the American Heart Association\u2019s PREVENT risk score for cardiovascular risk prediction in a multiethnic population. Nat Med. 2025;31(8):2655\u201362. https:\/\/doi.org\/10.1038\/s41591-025-03789-2.","journal-title":"Nat Med"},{"issue":"9","key":"473_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.32164","volume":"8","author":"MS Lee","year":"2025","unstructured":"Lee MS, Onwuzurike J, Wu YL, Palmer-Toy DE, An J, Chen W. PREVENT and PCE models for estimating ASCVD risk stratified by statin exposure. JAMA Netw Open. 2025;8(9):e2532164. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.32164.","journal-title":"JAMA Netw Open"},{"issue":"6 Pt 1","key":"473_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101825","volume":"4","author":"BS Murphy","year":"2025","unstructured":"Murphy BS, Hershey MS, Huang S, Nam Y, Post WS, McClelland RL, et al. PREVENT risk score vs the pooled cohort equations in MESA. JACC Adv. 2025;4(6 Pt 1):101825. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101825.","journal-title":"JACC Adv"},{"issue":"4","key":"473_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.039454","volume":"14","author":"H Zhou","year":"2025","unstructured":"Zhou H, Zhang Y, Zhou MM, Choi SK, Reynolds K, Harrison TN, et al. Evaluation and comparison of the PREVENT and pooled cohort equations for 10-year atherosclerotic cardiovascular risk prediction. J Am Heart Assoc. 2025;14(4):e039454. https:\/\/doi.org\/10.1161\/JAHA.124.039454.","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"473_CR44","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148(24):1982\u20132004. https:\/\/doi.org\/10.1161\/CIR.0000000000001191.","journal-title":"Circulation"},{"issue":"21","key":"473_CR45","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jacc.2024.02.053","volume":"83","author":"RV Nielsen","year":"2024","unstructured":"Nielsen RV, Fuster V, Bundgaard H, Fuster JJ, Johri AM, Kofoed KF, et al. Personalized intervention based on early detection of atherosclerosis. J Am Coll Cardiol. 2024;83(21):2112\u201327. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.053.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"473_CR46","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jacc.2021.12.016","volume":"79","author":"NJ Stone","year":"2022","unstructured":"Stone NJ, Smith SC, Orringer CE, Rigotti NA, Navar AM, Khan SS, et al. Managing atherosclerotic cardiovascular risk in young adults. J Am Coll Cardiol. 2022;79(8):819\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.016.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"473_CR47","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamacardio.2022.2641","volume":"7","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, An J, Reynolds K, Safford MM, Muntner P, Moran AE. Trends of elevated low-density lipoprotein cholesterol, awareness, and screening among young adults in the US, 2003-2020. JAMA Cardiol. 2022;7(10):1079. https:\/\/doi.org\/10.1001\/jamacardio.2022.2641.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"473_CR48","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","volume":"133","author":"SD De Ferranti","year":"2016","unstructured":"De Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation. 2016;133(11):1067\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018791.","journal-title":"Circulation"},{"issue":"3","key":"473_CR49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jama.2023.8867","volume":"330","author":"JM Guirguis-Blake","year":"2023","unstructured":"Guirguis-Blake JM, Evans CV, Coppola EL, Redmond N, Perdue LA. Screening for lipid disorders in children and adolescents: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2023;330(3):261. https:\/\/doi.org\/10.1001\/jama.2023.8867.","journal-title":"JAMA"},{"issue":"15","key":"473_CR50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620.","journal-title":"Circulation"},{"issue":"7","key":"473_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1701131.","journal-title":"N Engl J Med"},{"issue":"10349","key":"473_CR52","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"BK Kim","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00916-3.","journal-title":"Lancet"},{"issue":"25","key":"473_CR53","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","volume":"39","author":"MJ Budoff","year":"2018","unstructured":"Budoff MJ, Young R, Burke G, Jeffrey Carr J, Detrano RC, Folsom AR, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J. 2018;39(25):2401\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehy217.","journal-title":"Eur Heart J"},{"issue":"5","key":"473_CR54","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1001\/jamacardio.2024.5644","volume":"10","author":"AR Zheutlin","year":"2025","unstructured":"Zheutlin AR, Chokshi AK, Wilkins JT, Stone NJ. Coronary artery calcium testing\u2014too early, too late, too often. JAMA Cardiol. 2025;10(5):503. https:\/\/doi.org\/10.1001\/jamacardio.2024.5644.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"473_CR55","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2304146.","journal-title":"N Engl J Med"},{"issue":"23","key":"473_CR56","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.115.016857","volume":"132","author":"S Mora","year":"2015","unstructured":"Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial. Circulation. 2015;132(23):2220\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016857.","journal-title":"Circulation"},{"issue":"23","key":"473_CR57","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.jacc.2024.03.423","volume":"83","author":"CDL Johannesen","year":"2024","unstructured":"Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess apolipoprotein B and cardiovascular risk in women and men. JACC. 2024;83(23):2262\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.423.","journal-title":"JACC"},{"issue":"3","key":"473_CR58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1161\/CIRCULATIONAHA.117.032463","volume":"138","author":"V Sathiyakumar","year":"2018","unstructured":"Sathiyakumar V, Park J, Quispe R, Elshazly MB, Michos ED, Banach M, et al. Impact of novel low-density lipoprotein-cholesterol assessment on the utility of secondary non-high-density lipoprotein-C and apolipoprotein B targets in selected worldwide dyslipidemia guidelines. Circulation. 2018;138(3):244\u201354. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032463.","journal-title":"Circulation"},{"issue":"8","key":"473_CR59","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","volume":"37","author":"GJ Pearson","year":"2021","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129\u201350. https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016.","journal-title":"Can J Cardiol"},{"issue":"8","key":"473_CR60","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339\u201359. https:\/\/doi.org\/10.1194\/jlr.R067314.","journal-title":"J Lipid Res"},{"issue":"3","key":"473_CR61","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","volume":"18","author":"ML Koschinsky","year":"2019","unstructured":"Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2019;18(3):e308\u201319. https:\/\/doi.org\/10.1016\/j.jacl.2024.03.001.","journal-title":"J Clin Lipidol"},{"issue":"39","key":"473_CR62","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"issue":"4","key":"473_CR63","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1194\/jlr.R061648","volume":"57","author":"SM Marcovina","year":"2016","unstructured":"Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526\u201337. https:\/\/doi.org\/10.1194\/jlr.R061648.","journal-title":"J Lipid Res"},{"issue":"3","key":"473_CR64","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","volume":"67","author":"SM Marcovina","year":"2021","unstructured":"Marcovina SM, Clouet-Foraison N, Koschinsky ML, Lowenthal MS, Orquillas A, Boffa MB, et al. Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a). Clin Chem. 2021;67(3):490\u20139. https:\/\/doi.org\/10.1093\/clinchem\/hvaa324.","journal-title":"Clin Chem"},{"issue":"10155","key":"473_CR65","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(18)31652-0.","journal-title":"Lancet"},{"key":"473_CR66","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","volume":"355","author":"SB Simony","year":"2022","unstructured":"Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen general population study. Atherosclerosis. 2022;355:76\u201382. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.1023.","journal-title":"Atherosclerosis"},{"key":"473_CR67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.maturitas.2022.09.012","volume":"167","author":"P Anagnostis","year":"2023","unstructured":"Anagnostis P, Antza C, Trakatelli C, Lambrinoudaki I, Goulis DG, Kotsis V. The effect of menopause on lipoprotein (a) concentrations: a systematic review and meta-analysis. Maturitas. 2023;167:39\u201345. https:\/\/doi.org\/10.1016\/j.maturitas.2022.09.012.","journal-title":"Maturitas"},{"issue":"24","key":"473_CR68","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehz310.","journal-title":"Eur Heart J"},{"issue":"5","key":"473_CR69","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","volume":"29","author":"LM De Boer","year":"2022","unstructured":"De Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(5):779\u201392. https:\/\/doi.org\/10.1093\/eurjpc\/zwab171.","journal-title":"Eur J Prev Cardiol"},{"issue":"44","key":"473_CR70","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","volume":"41","author":"M Szarek","year":"2020","unstructured":"Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41(44):4245\u201355. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa649.","journal-title":"Eur Heart J"},{"issue":"12","key":"473_CR71","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial. Circulation. 2019;139(12):1483\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184.","journal-title":"Circulation"},{"issue":"21","key":"473_CR72","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.jacc.2025.09.015","volume":"86","author":"HN Jung","year":"2025","unstructured":"Jung HN, Heo JH, Kim MJ, Han KD, Kang JG, Lee SJ. Remnant cholesterol as an independent cardiovascular risk factor in young adults. J Am Coll Cardiol. 2025;86(21):2047\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2025.09.015.","journal-title":"J Am Coll Cardiol"},{"key":"473_CR73","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj M, McCoy RG, Balapattabi K, Bannuru RR, Bellini NJ, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142026. Diabetes Care. 2026 Jan 1;49(Supplement_1):S216\u201345. https:\/\/doi.org\/10.2337\/dc26-S010","DOI":"10.2337\/dc26-S010"},{"issue":"2","key":"473_CR74","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/jcm14020643","volume":"14","author":"E Abidor","year":"2025","unstructured":"Abidor E, Achkar M, Al Saidi I, Lather T, Jdaidani J, Agarwal A, et al. Comprehensive review of lipid management in chronic kidney disease and hemodialysis patients: conventional approaches, and challenges for cardiovascular risk reduction. J Clin Med. 2025;14(2):643. https:\/\/doi.org\/10.3390\/jcm14020643.","journal-title":"J Clin Med"},{"issue":"6","key":"473_CR75","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner C, Tonelli M, The Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303\u20139. https:\/\/doi.org\/10.1038\/ki.2014.31.","journal-title":"Kidney Int"},{"issue":"9784","key":"473_CR76","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(11)60739-3.","journal-title":"Lancet"},{"issue":"3","key":"473_CR77","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u201348. https:\/\/doi.org\/10.1056\/NEJMoa043545.","journal-title":"N Engl J Med"},{"issue":"14","key":"473_CR78","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa0810177.","journal-title":"N Engl J Med"},{"issue":"5","key":"473_CR79","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1210\/jc.2019-00195","volume":"104","author":"OJ Ponce","year":"2019","unstructured":"Ponce OJ, Larrea-Mantilla L, Hemmingsen B, Serrano V, Rodriguez-Gutierrez R, Spencer-Bonilla G, et al. Lipid-lowering agents in older individuals: a systematic review and meta-analysis of randomized clinical trials. J Clin Endocrinol Metab. 2019;104(5):1585\u201394. https:\/\/doi.org\/10.1210\/jc.2019-00195.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9346","key":"473_CR80","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(02)11600-X.","journal-title":"Lancet"},{"issue":"1","key":"473_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01257-9","volume":"27","author":"A Bao","year":"2025","unstructured":"Bao A, Karalis DG. Statin therapy for primary and secondary prevention in older adults. Curr Atheroscler Rep. 2025;27(1):11. https:\/\/doi.org\/10.1007\/s11883-024-01257-9.","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"473_CR82","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.jacc.2025.10.052","volume":"87","author":"TN Harrison","year":"2026","unstructured":"Harrison TN, Zhang Y, Choi SK, Pak KJ, Zhou H, Morrissette K, et al. Follow-up lipid testing and statin initiation among young adults in a U.S. health care system. JACC. 2026;87(11):1327\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2025.10.052.","journal-title":"JACC"},{"issue":"5","key":"473_CR83","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1016\/j.jacl.2024.05.005","volume":"18","author":"A Agarwala","year":"2024","unstructured":"Agarwala A, Dixon DL, Gianos E, Kirkpatrick CF, Michos ED, Satish P, et al. Dyslipidemia management in women of reproductive potential: an expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e664\u201384. https:\/\/doi.org\/10.1016\/j.jacl.2024.05.005.","journal-title":"J Clin Lipidol"},{"issue":"25","key":"473_CR84","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.jacc.2009.10.009","volume":"54","author":"KA Matthews","year":"2009","unstructured":"Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54(25):2366\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2009.10.009.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"473_CR85","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","volume":"1","author":"T Muka","year":"2016","unstructured":"Muka T, Oliver-Williams C, Kunutsor S, Laven JSE, Fauser BCJM, Chowdhury R, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767. https:\/\/doi.org\/10.1001\/jamacardio.2016.2415.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"473_CR86","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361\u201375. https:\/\/doi.org\/10.1016\/j.jacl.2022.05.068.","journal-title":"J Clin Lipidol"},{"issue":"15","key":"473_CR87","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580. https:\/\/doi.org\/10.1001\/jama.2016.3608.","journal-title":"JAMA"},{"key":"473_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n135","author":"E Herrett","year":"2021","unstructured":"Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n135.","journal-title":"BMJ"},{"issue":"12","key":"473_CR89","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","volume":"78","author":"JP Howard","year":"2021","unstructured":"Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.022.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"473_CR90","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526\u201334. https:\/\/doi.org\/10.7326\/0003-4819-158-7-201304020-00004.","journal-title":"Ann Intern Med"},{"issue":"16","key":"473_CR91","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"1","key":"473_CR92","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/phar.4635","volume":"45","author":"CL Garwood","year":"2025","unstructured":"Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9\u2010directed therapies to reduce LDL\u2010C and ASCVD risk: a state\u2010of\u2010the\u2010art review. Pharmacother J Hum Pharmacol Drug Ther. 2025;45(1):54\u201365. https:\/\/doi.org\/10.1002\/phar.4635.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"3","key":"473_CR93","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"N Engl J Med"},{"issue":"9","key":"473_CR94","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","volume":"50","author":"AV Khera","year":"2018","unstructured":"Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219\u201324. https:\/\/doi.org\/10.1038\/s41588-018-0183-z.","journal-title":"Nat Genet"},{"issue":"7","key":"473_CR95","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-023-02429-x","volume":"29","author":"AP Patel","year":"2023","unstructured":"Patel AP, Wang M, Ruan Y, Koyama S, Clarke SL, Yang X, et al. A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. Nat Med. 2023;29(7):1793\u2013803. https:\/\/doi.org\/10.1038\/s41591-023-02429-x.","journal-title":"Nat Med"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00473-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:24:21Z","timestamp":1788405861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00473-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00473-5","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors (Andrew Carlson, Zaid A. Zayyad, Stefanie Driesenga, Peter Boxley, Atreya Mishra, Omar Uraizee, Rediat Ephrem, Runze Zhang, Zachary Natsheh, and Adhir R Shroff) have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously published studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}